FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DC	20549	
vasimigton,	D.O.	20040	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Gillies Hunter						2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]							(Che	ck all applic Directo	cable)	g Per	son(s) to Iss 10% Ov Other (s	vner	
(Last) C/O AEI	,	rst) ((Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/23/2024							X	below)		CAL	below) OFFICEI	`	
930 WINTER STREET, SUITE M-500					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	'					
(Street) WALTH	AM M	A	02451											X		iled by Mor		orting Perso n One Repo	- 1
(City)	(Si	tate) ((Zip)		Rule 10b5-1(c) Transaction Indication X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is interest satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								that is intend	ed to					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Da		2. Transaction Date (Month/Day/Year)		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Dispo Code (Instr. 5)		Dispose	ities Acqui d Of (D) (In		4 and Securiti		es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) c (D)	r Pr	ice	Transac (Instr. 3	tion(s)			(111001.4)
Common Stock 02/2			02/23	′2024		M ⁽¹⁾		511	A	\$	1.74	3,762			D				
Common	Common Stock 02/23/2024				4			S ⁽¹⁾	S ⁽¹⁾ 511 D		\$	19.5	3,251			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (8)				6. Date Ex Expiration (Month/Da	Date		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		rity	3. Price of Derivative Security Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Over the second of the second	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amo or Num of Shar	ber					
Stock Option (Right to	\$1.74	02/23/2024			M ⁽¹⁾			511	(2)	09	9/03/2030	Common Stock	51	1	\$0	3,014		D	

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
- 2. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

/s/ George A. Eldridge, 02/27/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.